EXPE vs KURA · P/E 20, rev $7.74B vs rev $20.9M
Expedia Group Inc. (EXPE) versus Kura Oncology Inc (KURA) — a side-by-side from cached financials, not a winner call.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Kura Oncology Inc (KURA) is a biotechnology company listed on NASDAQ.
Latest reported EXPE revenue for 2026-06-30 was $7.74B. Net income was $872.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Latest reported KURA revenue for 2026-06-30 was $20.9M. Net income was -$68.3M. Revenue was up 14.3% from 2026-03-31 to 2026-06-30. KURA currently screens at market cap $861.1M.
EXPE currently screens at market cap $21.71B and trailing P/E 20.4. KURA currently screens at market cap $861.1M.
Not investment advice. Open the EXPE and KURA stock pages for the full models.
Not investment advice.